therapeutic action: Reduced nephrotoxicity

The In vitro Effect of Nanoliposomal Amphotericin B Against Rhizopus arrhizus Isolated From COVID-19-Associated Mucormycosis Patients

mycolabadmin

Scientists tested a new nano-formulation of the antifungal drug amphotericin B against a dangerous fungus (Rhizopus arrhizus) that infected COVID-19 patients with mucormycosis. The nanoliposomal version of the drug worked much better than regular amphotericin B and other antifungal medications currently used, showing much lower concentrations needed to kill the fungus. This research suggests the new nano-formulation could be a more effective treatment option for patients with this serious COVID-19 related fungal infection.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

This study reviewed clinical trials comparing a newer antifungal drug called isavuconazole with other commonly used antifungal medications for treating serious fungal infections, particularly in patients with weakened immune systems. The research found that isavuconazole works just as well as other antifungal drugs but may have fewer side effects, especially liver problems. When compared directly with voriconazole, isavuconazole showed fewer drug-related side effects overall, making it a good alternative option for patients who cannot tolerate other antifungal treatments.

Read More »

In vitro activity of SF001: a next-generation polyene versus amphotericin B

mycolabadmin

This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.

Read More »
Scroll to Top